Tower Bridge Advisors Has $2.84 Million Stock Position in Roche Holding AG (OTCMKTS:RHHBY)

Tower Bridge Advisors reduced its stake in shares of Roche Holding AG (OTCMKTS:RHHBY) by 2.2% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 69,093 shares of the company’s stock after selling 1,526 shares during the period. Tower Bridge Advisors’ holdings in Roche were worth $2,836,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. HighPoint Advisor Group LLC raised its stake in shares of Roche by 2.8% in the 4th quarter. HighPoint Advisor Group LLC now owns 11,091 shares of the company’s stock valued at $387,000 after purchasing an additional 304 shares during the period. Fulton Bank N.A. raised its stake in shares of Roche by 2.6% in the 1st quarter. Fulton Bank N.A. now owns 12,620 shares of the company’s stock valued at $518,000 after purchasing an additional 314 shares during the period. GAMMA Investing LLC raised its stake in shares of Roche by 59.5% in the 1st quarter. GAMMA Investing LLC now owns 12,850 shares of the company’s stock valued at $529,000 after purchasing an additional 4,794 shares during the period. Confluence Investment Management LLC raised its stake in shares of Roche by 3.6% in the 1st quarter. Confluence Investment Management LLC now owns 14,491 shares of the company’s stock valued at $596,000 after purchasing an additional 510 shares during the period. Finally, Minot DeBlois Advisors LLC acquired a new stake in shares of Roche in the 4th quarter valued at about $752,000.

Roche Trading Down 0.7%

OTCMKTS:RHHBY opened at $40.31 on Wednesday. Roche Holding AG has a 52-week low of $34.10 and a 52-week high of $44.31. The company has a quick ratio of 1.20, a current ratio of 1.48 and a debt-to-equity ratio of 0.85. The stock’s 50-day simple moving average is $40.38 and its 200 day simple moving average is $40.13.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Hsbc Global Res downgraded Roche from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 28th. HSBC downgraded Roche from a “buy” rating to a “hold” rating in a research report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Roche Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.